

# TO Testing

**The Tempus Tumor Origin (TO) is an AI-driven test, analyzing information from next-generation sequencing performed as part of a separately-ordered Tempus|xT test.** By using RNA expression data, the validated TO test indicates the most likely primary and potential tumor origin from 64 possible diagnostic subtypes. When paired with xT, the TO results may provide insight into the tumor's diagnosis and site of origin that may be used to guide patient care and clinical trial eligibility.

## TO RESULTS

The Tempus TO test is for cancers of unknown primary (CUPs) and other tumors of uncertain origin and may help clinicians make more informed decisions where other clinical information, like imaging and immunohistochemistry results, do not provide a definitive diagnosis.

### Harnessing the power of RNA


RNA sequencing data derived from xT provides the most likely primary and potential tumor origin by analyzing RNA expression, providing ordering physicians with insight that can support clinical decisions they make for their patients.

### Pathologist review

In certain cases, the test may include further interpretive analysis of the test result from a Tempus pathologist based on the patient's progress notes, pathology reports, and molecular test results.

### Saves time and tissue

By leveraging the sequencing information generated from an xT test, the TO test can be ordered without additional tissue, making it easier for you and your patient.



20,000+ samples with RNA sequencing data were used to train the TO model

5,500+ additional samples used for TO test validation

Tempus performs whole-transcriptome RNA sequencing on all eligible xT samples. Whole transcriptome RNA profiling with validated fusion detection provides more information for origin determination. **Our robust RNA database allows us to develop clinically relevant tests like TO to ultimately transform the way patients are treated.**